Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics presented positive Phase 2a follow-up data for RAP-219, showing a 90% median reduction in clinical seizures in weeks 9-12 and 59% in weeks 13-16. The study confirmed an extended 22-day half-life, supporting sustained therapeutic exposure and efficacy without new safety signals during the off-treatment period.
Key figures
- Drug Name
- RAP-219
- Phase Of Trial
- Phase 2a
- Half life days
- 22
- Seizure reduction weeks 9 12
- 90%
- Seizure reduction weeks 13 16
- 59%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.